Fludarabine
Neuroendocrine Tumors
Cancer Institute and Hospital, Chinese Academy of Medical SciencesSmall moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 73/ 100
Competitive context
61 Active assets in the Neuroendocrine Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 Fox Chase Cancer Center | Phase 3 | BB |
FLUOROURACILUM ITM Solucin GmbH | Phase 3 | BB |
Irinotecan First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | BB |
Eloxatin ITM Solucin GmbH | Phase 3 | BB |
Pasireotide RECORDATI GROUP | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →